A systematic review published in JAMA covering 84 popular dietary supplements found that only 12 had strong evidence from randomized controlled trials supporting their claimed health benefits. The most evidence-supported supplements for specific populations include folic acid for pregnancy, vitamin D for individuals with documented deficiency, and omega-3 fatty acids for cardiovascular risk reduction in patients with elevated triglycerides.
The supplement industry generates approximately 61 billion dollars in annual US sales despite the weak evidence base for most products. Regulatory oversight remains minimal because supplements are not required to demonstrate efficacy before being sold, unlike pharmaceutical drugs. The FTC has pursued deceptive advertising claims, but the legal threshold for enforcement allows companies to make vague structure-function claims that consumers interpret as therapeutic promises.
